Vasoactive drug use in septic shock

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 6, 2004, Pages 673-681

  Stanchina, Michael L ^a,b   Levy, Mitchell M ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Sepsis; Shock; Vasodilators

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR; AMRINONE; CATECHOLAMINE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; METHYLENE BLUE; MILRINONE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; VASODILATOR AGENT; VASOPRESSIN;

CRYSTALLOID; DRUG EFFICACY; HUMAN; MORTALITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 11144343285     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-860981     Document Type: Review

References (73)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-1310
2. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
3. Rivers E, Nguyen B, Havasted S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377
4. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med 1999;340:1834-1835
5. Levy MM, Fink MP, Marshall J, et al. SCCM/ESICM/ ACCP/ATS/SIS international Sepsis Definitions Conference. Crit Care Med 2001;31:1250-1256
6. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999;96:12541-12546
7. Oberholzer C, Oberholzer A, Clare-Salzer M, Moldawer LL. Apoptosis in sepsis a new target for therapeutic exploration. FASEB J 2001;15:879-892
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150
9. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-242
10. Fink MP. Bench-to-bedside review: cytopathic hypoxia. Crit Care 2002;6:491-499
11. Martin C, Vivand X, Leone M, Thiron X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-2765
12. Kirchheim HR, Ehmke E, Hackenthal E, et al. Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. Pflugers Arch 1987;410:441-449
13. Manning RD, Guyton AC. Dynamics of fluid distribution between the blood and interstitium during overhydration. Am J Physiol 1980;238:H645-H651
14. Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of autoregulation in acute renal failure. Am J Physiol 1984;246:F379-F386
15. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986;
16. Yu M, Levy MM, Smith P, Takiguchi SA, Miyaski A, Myers SA. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled trial. Crit Care Med 1993;21:830-838
17. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-1722
18. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025-1032
19. Kobilka B. Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 1992;15:87-114
20. Bohm M, Diet F, Feiler G, Kemkes B, Erdman E. Alpha-adrenoreceptors and alpha-adrenoreceptor-mediated positive ionotropic effectsin failing human myocardium. J Cardiovasc Pharmacol 1988;12:357-364
21. Govier WC. Myocardial alpha adrenergic receptors and their role in the production of a positive ionotropic effect by sympathomimetic agents. J Pharmacol Exp 1968;159:82-90
22. Kaufman AJ, Hall JA, Murray KJ, Wells FC, Brown MJ. A comparison of the effects of adrenaline and noradrenaline on the human heart: the role of beta-1 and beta-2 adrenoreceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 1989;10(suppl B):29-37
23. Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR. Endocrine renal and hemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 1985;60:821-826
24. Minniman KP. Alpha1-adrenergic receptor subtypes, inositol phosphates, and sources of cell calcium. Pharmacol Rev 1988;40:87-119
25. Sibbald WJ, Fox G, Martin C. Abnormalities of vascular reactivity in the sepsis syndrome. Chest 1991;100:155S-159S
26. McKenna TM, Martin FM, Chernow B, Briglia FA. Vascular endothelium contributes to decreased aortic contractility in experimental sepsis. Circ Shock 1986;19:267-273
27. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: A prospective, randomized study. Intensive Care Med 1997;23:282-287
28. Desjars P, Pinaud M, Tasseau F, et al. A reaapraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987;15:134-137
29. Hesselvik JF, Brodin B. Low-dose norepinephrine in patients with septic shock and oliguria. Crit Care Med 1989;17:179-180
30. Meadows D, Edwards JD, Wilkins RG, et al. Reversal of intractable shock with norepinephrine therapy. Crit Care Med 1988;16:663-667
31. Martin C, Papaian L, Perrin G, et al. Norepinephrine or dopamine for the treatement of hyperdynamic shock. Chest 1993;103:1826-1831
32. Redl-Wenzl EM, Armbruster C, Edelman G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19:151-154
33. Martin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18:282-285
34. Conger JD, Robinette JB, Guggenheim SJ. Effect of acetylcholine on the early phase of reversible norepinephrine-induced actue renal failure. Kidney Int 1981;19:399-409
35. Ruokonen E, Takala J, Kari A, et al. Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993;21:1296-1303
36. Marik PE, Mohedin M. The contrasting efects of dopamine and norepinephrine on systemic and splanchnic oxygenatio utilization in hyperdynamic sepsis. JAMA 1994;271:1354-1357
37. DeBacker D, Creteur J, Silva E, Vincent JL. Effects of doapamine, norepinephrine and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003;31:1659-1667
38. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo controlled randomised trial. Australian and New Aealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143
39. Reginer B, Safran D, Carlet J, et al. Comparative hemodynamic effects of dopamine and dobutamine in septic shock. Intensive Care Med 1979;5:115-120
40. Hannemann L, Reinhart K, Grenzer O, et al. Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995;23:1962-1970
41. Neviere R, Mathiew D, Chagnon JL,et al. The contrasting effects of dobutamine and dopamine on mucosal perfusion in septic patients. Am J Respir Crit Care Med 1996;154:1684-1688
42. Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine and norepinephrine for oxygen delivery and uptake in septic shock. Intensive Care Med 1997;23:31-37
43. Schwanz DR, Malhotra A, Fink MP. Cytopathic hypoxia in sepsis: an overview. Sepsis 1998;2:279-289
44. Gregory JS, Bonfiglio MF, Dasta JF, Reilly TE, Townsend MC, Flancbaum L. Experience with phenylephrine as a component of a pharmacologic support of septic shock. Crit Care Med 1991;19:1395-1400
45. Flancbaum L, Dick M, Dasta J, et al. A dose-response study of phenylephrine in critically ill septic surgical patients. Eur J Clin Pharmacol 1997;51:461-465
46. Yamazaki T, Shimada Y, Taenaka N. Circulatory responses to afterloading wtih phenylephrine in hyperdynamic sepsis. Crit Care Med 1982;10:432-435
47. Duranteau J, Sitbon P, Teboul JL, et al. Effects of epinephrine, norepinephrine, or the combination of norepinephrine on gastric mucosa in septic shock. Crit Care Med 1999;27:893-900
48. Cohen RI, Shapir Y, Davis A, Loona R, Scharf SM. Comparison between selective and nonselective nitric oxide synthase inhibition and phenylephrine in normal and endotoxic swine. Crit Care Med 2000;28:3257-3267
49. Wilson W, Lipman J, Scribante J, et al. Septic shock: does adrenaline have a role as a first-line inotropic agent? Anaesth Intensive Care 1992;20:470-474
50. Mackenzie SJ, Kapadia F, Nimmo GR. Adrenaline in the treatment of septic shock: Effects on hemodynamics and oxygen transport. Intensive Care Med 1991;17:36-39
51. Day NP, Phu NH, Bethell DP, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996;348:219-223
52. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997;25:399-404
53. Parker MM, Shelhamer JH, Natanson C, Ailing DW, Parillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987;15:923-929
54. Liu M, Wu LL. Heart sarcolemmal calcium transport in endotoxic shock, II: Mechanism of inpairment in ATP-dependent calcium transport. Mol Cell Biochem 1992;112:135-142
55. Bensard DD, Banerjee A, McIntyre RC, et al. Endotoxin disrupts beta-adrenergic signal transduction in the heart. Arch Surg 1994;129:198-204
56. Kinkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative ionotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-389
57. Jardin F, Sportiche M, Bazin M, et al. Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med 1981;9:329-332
58. De Backer D, Berre J, Zhange H. Relationship between oxygen uptake and oxygen delivery in septic patients: effect of prostacyclin versus dobutamine. Crit Care Med 1993;21:1658-1664
59. Hannemann L, Reinhart K, Meier-Hellmann A, et al. Dopexamine hydrochloride in septic shock. Chest 1996;109:756-760
60. Cain SM, Curtis SE. Systemic and regional oxygen uptake and lactate flux in endotoxic dogs infused with dopexamine. Crit Care Med 1991;19:1552-1560
61. Vincent JL, Reuse C, Kahn RJ. Administration of dopexamine, a new adrenergic agent in cardiorespiratory failure. Chest 1989;96:1233-1236
62. Smithies M, Yee TH, Jackson L, et al. Protecting the gut and liver in the critically ill: effects of dopexamine. Crit Care Med 1994;22:789-795
63. Spronk PE, Ince C, Gardien MJ, Mathura KR, Oudemansvan Straaten HM, Zandstra DF. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002;360:1395-1396
64. Preiser JC, Sun Q, Hadj-Sadok D, Vincent JL. Differential effects of a selective inhibitor of soluble guanylyl cyclase on global and regional hemodynamics during canine endotoxic shock. Shock 2003;20:465-468
65. Webb PJ, Westwick J, Scully MF, Zahavi J, Kakkar VV. Do prostacyclin and thromboxane play a role in endotoxic shock? Br J Surg 1981;68:720-724
66. Hannemann L, Reinhart K, Meier-Hellmann A, Bredle DL. Prostacyclin in septic shock. Chest 1994;105:1504-1510
67. Radermacher P, Buhl R, Santak B, et al. The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 1995;21:414-421
68. Daemen-Gubbels CRGH, Groeneveld PHP, Groeneveld ABJ, Van Kamp GJ, Bronsveld W, Thijs LG. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-1370
69. Mayer B, Brunner F, Schnidt K. Novel actions of methylene blue. Eur Heart J 1994;14(suppl):22-26
70. Landry DW, Levin HR, Gallant EM, et al. Vasopressin presser hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-1282
71. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-595
72. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-582
73. Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of milrinone lactate in pediatric patients with septic shock: a prospective, randomized, placebo-controlled interventional study. Chest 1996;109:1302-1311